Medical Oncologist
Hyderabad's Dedicated Blood Cancer Panel
Best Blood Cancer Doctors in Hyderabad - CION's Dedicated Blood Cancer Panel
"Blood cancer" is an umbrella term — not a single disease. It covers leukemia, lymphoma, multiple myeloma, MDS, and myeloproliferative neoplasms — five distinct cancer groups, each needing different urgency, different specialists, different treatment. The first job at any consultation is precise classification through bone marrow biopsy and hematopathology.
- Hematologist-led care - Dr. Basudev Pokhrel (DM Clinical Hematology) leads our blood cancer and stem cell transplant pathway
- Acute leukemia emergency pathway - Same-day or next-day hospital admission for newly diagnosed AML and ALL
- Stem cell transplant capability - Autologous SCT for multiple myeloma, allogeneic SCT for high-risk acute leukemia
- Modern targeted agents - TKI therapy for CML, ibrutinib/venetoclax for CLL, Dara-VRd for myeloma, CAR-T coordination
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The CION Blood Cancer Panel — 16 Specialists
Hematology, Medical, Radiation & Surgical Oncology — all under one tumour board
Hematology and stem cell transplant leadership for acute leukemia and SCT-eligible cases. Medical oncology co-management for chronic blood cancers and outpatient chemotherapy. Radiation oncology for TBI, ISRT, and CNS prophylaxis. Surgical oncology for diagnostic biopsy and selected splenectomy.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Acute Blood Cancer Emergency Pathway
Suspected acute leukemia? Call us now.
For suspected acute leukemia — significantly abnormal CBC with blasts, bleeding, or critical pancytopenia — CION coordinates same-day or next-day hospital admission. Do not wait for an outpatient appointment.
The Disambiguation
Which Blood Cancer Do You Have?
Blood cancer is the most umbrella-term-dependent cancer group on this site. Patients searching "blood cancer doctors" may have any of five very different hematological cancers. Below is the classification — with links to dedicated pathway pages for leukemia and lymphoma, and direct pathway depth for multiple myeloma and rarer hematological malignancies on this page.
| Blood Cancer Type | What it is | Lead specialty & treatment |
|---|---|---|
| Leukemia | Cancer of blood-forming cells in bone marrow. Acute (AML, ALL) and Chronic (CML, CLL) subtypes. | Hematology-led. Acute leukemias are medical emergencies requiring hospitalisation; chronic leukemias managed outpatient. See our dedicated leukemia doctors page for detailed pathway. |
| Lymphoma | Cancer of lymphocytes (immune cells) in lymph nodes and lymphoid tissue. Hodgkin and Non-Hodgkin (70+ subtypes). | Medical oncology + hematology led. ABVD for Hodgkin, R-CHOP for aggressive B-cell NHL. PET-adapted treatment. See our dedicated lymphoma doctors page for detailed pathway. |
| Multiple Myeloma | Cancer of plasma cells (antibody-producing immune cells) in bone marrow. Causes bone lesions, kidney problems, anemia, high calcium. | Hematology + medical oncology. Treatment: triplet/quadruplet induction (VRd, Dara-VRd) → autologous stem cell transplant → lenalidomide maintenance. CAR-T and bispecifics for relapsed disease. |
| Myelodysplastic Syndromes (MDS) | Pre-leukemic bone marrow disorders — abnormal blood cell production, risk of progression to AML. | Hematology-led. Low-risk MDS often watch-and-wait with supportive care; high-risk MDS treated with azacitidine, decitabine, or allogeneic SCT. |
| Myeloproliferative Neoplasms (MPN) | Chronic disorders of blood cell production — polycythemia vera, essential thrombocythemia, primary myelofibrosis. | Hematology-led. JAK2/CALR/MPL mutation testing guides classification. Treatment varies by type — phlebotomy + aspirin for PV, hydroxyurea or ruxolitinib for myelofibrosis. |
| Hematopathologist | Tissue and bone marrow diagnosis — morphology, flow cytometry, cytogenetics, molecular markers. | Critical specialty for accurate blood cancer classification. WHO 2022 classification requires combined morphology + immunophenotype + cytogenetics + molecular markers. Treatment cannot be planned without precise hematopathology classification. |
Which subtype matches your situation?
Use this as a quick guide. Any CION oncologist can review your case in 45 minutes.
- Sudden onset of fatigue, bruising, frequent infections, fever, abnormal CBC with blasts Suspected acute leukemia. Urgent hematology evaluation, possibly same-day hospital admission. See our leukemia doctors page.
- Persistent enlarged lymph nodes (>4 weeks), unexplained fever, night sweats, weight loss Suspected lymphoma. Excisional lymph node biopsy with hematopathology review. See our lymphoma doctors page.
- Bone pain, anemia, kidney problems, high calcium, recurrent infections Suspected multiple myeloma. Serum protein electrophoresis (SPEP), free light chain assay, bone marrow biopsy with FISH for cytogenetics. CRAB criteria assessment.
- Chronic abnormal CBC — high WBC with mature cells, high platelets, high hemoglobin Possible chronic leukemia (CML, CLL) or myeloproliferative neoplasm (PV, ET, MF). JAK2, CALR, MPL, BCR-ABL testing.
- Persistent anemia, low blood counts without obvious cause, abnormal cells on smear Possible myelodysplastic syndrome (MDS). Bone marrow biopsy with morphology, IPSS-R risk stratification.
- Confirmed blood cancer at outside centre, seeking comprehensive review CION's multidisciplinary tumour board reviews bone marrow, flow cytometry, cytogenetics, and existing recommendation. Free written second opinion.
Patient Decision Framework
Seven Questions to Ask Before You Choose a Blood Cancer Doctor
Blood cancer decisions require precise classification first. The questions below distinguish a centre that classifies precisely and treats modern-evidence-based protocols from one applying generic chemotherapy. Bring them to your first consultation — at CION, or anywhere else.
-
How many blood cancer cases — leukemia, lymphoma, myeloma — does this team treat in a year?
Blood cancer outcomes are volume-sensitive. High-volume centres see meaningful differences from low-volume ones in classification accuracy, treatment selection, and supportive care infrastructure.
-
Which type of blood cancer do I have — and how does that change everything?
Leukemia, lymphoma, myeloma, MDS, MPN are five very different cancers. A team that walks you through your precise diagnosis with hematopathology backing is one that takes classification seriously.
-
Is stem cell transplant available here — and would I be a candidate?
SCT is curative for many high-risk blood cancers — autologous for multiple myeloma, allogeneic for high-risk AML/ALL. A centre with SCT capability (or active coordination with SCT centres) is essential for any patient who might need it.
-
Who will personally manage my case across induction, consolidation, and follow-up?
Blood cancer treatment runs months for acute leukemia/lymphoma, years for chronic disease and myeloma maintenance. Continuity matters.
-
What molecular and cytogenetic testing will be done — and how will it guide treatment?
Modern blood cancer treatment is increasingly molecular-guided. FLT3/NPM1 for AML, FISH cytogenetics for myeloma, BCR-ABL for CML, IGHV/TP53 for CLL. A team that orders comprehensive testing and explains how results affect treatment is one current with modern care.
-
Will I get a written cost estimate covering everything — before treatment starts?
Blood cancer treatment involves prolonged hospitalisation, intensive supportive care, possible SCT, possibly long-term targeted therapy. A centre that discusses cost openly upfront respects your circumstances.
-
Will my case be discussed by a team of specialists together?
Blood cancer decisions cut across hematology, medical oncology, hematopathology, and radiation oncology. No single doctor sees the full picture alone.
Standards Dashboard
Diagnosis
Specialty Lead
Transplant
Myeloma
Emergency
CAR-T
Pathology
Lymphoma
Targeted Therapy
Tumour Board
Cost Transparency
Second Opinion
How CION Measures Up — Our Standards, in Numbers
The standards we hold ourselves to — for every blood cancer patient who walks through any of our 11 Hyderabad centres. Every number below is independently verifiable on request.
Precise classification at first consultation
Blood cancer is an umbrella term covering leukemia, lymphoma, multiple myeloma, MDS, and MPN — five very different cancer groups. Precise classification through bone marrow biopsy and hematopathology is the first step.
Hematologist-led care for hematological cancers
Blood cancers are best managed by a hematologist (DM Clinical Hematology). Dr. Basudev Pokhrel leads our hematology and SCT pathway.
Stem cell transplant capability
Autologous and allogeneic SCT for eligible patients — including multiple myeloma (autologous), AML (allogeneic for high-risk), ALL (allogeneic for high-risk), and selected lymphomas. Dr. Basudev Pokhrel leads SCT.
Multiple myeloma — modern triplet/quadruplet induction
VRd (bortezomib, lenalidomide, dexamethasone) or Dara-VRd (daratumumab + VRd) induction → autologous SCT → lenalidomide maintenance. Survival has more than doubled in the past decade.
Acute leukemia emergency pathway
AML and ALL are medical emergencies — same-day or next-day hospital admission. CION coordinates emergency admission for newly diagnosed acute leukemia.
CAR-T cell therapy coordination
For relapsed/refractory pediatric and young adult B-cell ALL, aggressive B-cell NHL, and multiple myeloma — coordination with accredited CAR-T centres for evaluation and treatment.
Hematopathology review for every case
WHO 2022 classification of hematological malignancies requires combined morphology + flow cytometry + cytogenetics + molecular markers. Specialist hematopathology review is part of every CION blood cancer case.
PET-adapted treatment for lymphoma
Interim PET-CT after 2 cycles guides treatment intensification or de-escalation for Hodgkin and aggressive NHL.
Modern targeted agents for chronic blood cancers
TKI therapy (imatinib, dasatinib, nilotinib) for CML. Ibrutinib, acalabrutinib, venetoclax for CLL. Ruxolitinib for myelofibrosis. JAK inhibitors and BCL2 inhibitors transforming chronic blood cancer care.
Multidisciplinary tumour board for every case
Hematology, medical oncology, hematopathology, radiation oncology — together — before any treatment decision.
Written, itemised cost estimate
Chemotherapy, hospitalisation, transfusion support, possible SCT — quoted in writing where feasible at start, with ongoing transparency.
Free written second opinion
Documented. Yours to keep. Take it to any doctor, anywhere.
How a Case Moves Through CION
How a Blood Cancer Case Actually Moves Through CION
From first call to long-term follow-up — the seven steps every blood cancer patient walks through at CION. No skipped steps. No rushed decisions.
-
First Consultation or Emergency Admission
For suspected acute blood cancer: same-day or next-day hospital admission. For chronic blood cancer or stable presentation: 45-minute outpatient consultation. All starting points lead to bone marrow biopsy for definitive diagnosis.
-
Bone Marrow Biopsy and Hematopathology
Bone marrow aspirate and biopsy with morphology, flow cytometry, cytogenetics (karyotype + FISH), and molecular markers per WHO 2022 classification. For multiple myeloma: serum protein electrophoresis, free light chains, urine protein, imaging (skeletal survey or PET-CT). For lymphoma: excisional node biopsy, PET-CT.
-
Multidisciplinary Tumour Board Discussion
Case presented to hematology, medical oncology, and hematopathology — together. Consensus on classification, risk stratification, protocol selection, and SCT consideration documented.
-
Subtype-Appropriate Treatment Initiation
Acute leukemia: induction chemotherapy (7+3 for AML, hyper-CVAD or pediatric-inspired for ALL). Lymphoma: ABVD or BV-AVD for Hodgkin, R-CHOP for DLBCL. Multiple myeloma: VRd or Dara-VRd induction. CML: TKI therapy. CLL: watch-and-wait or ibrutinib/venetoclax. MDS: azacitidine for high-risk.
-
Response Assessment and Consolidation
Bone marrow assessment for leukemia and myeloma. PET-CT for lymphoma. MRD monitoring where applicable. Consolidation chemotherapy, radiation, or stem cell transplant based on risk.
-
Stem Cell Transplant (Where Indicated)
Autologous SCT for multiple myeloma and selected lymphomas. Allogeneic SCT for high-risk acute leukemia and selected aggressive lymphoid malignancies. Donor identification, conditioning regimen selection, transplant care.
-
Maintenance, Long-Term Follow-Up, and Survivorship
Maintenance therapy as indicated (lenalidomide for myeloma post-SCT, hormonal therapy for some lymphomas, indefinite TKI for CML). Long-term follow-up: marrow surveillance, monitoring for late effects (cardiotoxicity, secondary cancers, GVHD for SCT patients), psychosocial support.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Take the next step with a team that does this every day
Precise classification. Hematologist-led care. Acute leukemia emergency pathway. Stem cell transplant capability. Modern targeted agents and CAR-T coordination. Multidisciplinary tumour board for every case. Free written second opinion.
This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified hematologist or oncologist for guidance specific to your medical condition.